Literature DB >> 1396809

The use of an exponential protocol for bicycle and treadmill exercise testing in patients with chronic cardiac failure.

M Riley1, D B Northridge, E Henderson, C F Stanford, D P Nicholls, H J Dargie.   

Abstract

We have studied a standardized exercise protocol suitable for use with a treadmill or bicycle (STEEP protocol) and compared it with a modified Bruce treadmill protocol in a group of patients with chronic cardiac failure. The STEEP protocol has been previously validated in normal subjects. Exercise time (6.79 +/- 2.42 vs 5.34 +/- 1.95 min, P < 0.05) and peak VO2 (16.66 +/- 4.09 vs 15.01 +/- 3.72 ml.min-1.kg-1, P < 0.05) were greater with the STEEP treadmill compared with the bicycle protocol, but VO2 was very similar at equal exercise stages in both modalities. Heart rate and respiratory exchange ratio tended to be greater during bicycle exercise at equal stages. Exercise time was greater with the modified Bruce protocol (9.00 +/- 3.02 min, P < 0.05) than with either STEEP protocol, but peak VO2 (17.13 +/- 4.52 ml.min-1.kg-1) was similar to that obtained with the STEEP treadmill test. We conclude that the STEEP protocol may be used to test patients with chronic cardiac failure, and that exercise times relate well in both treadmill and bicycle. The protocol should prove useful in studies involving a wide range of exercise capacities or both bicycle and treadmill exercise.

Entities:  

Mesh:

Year:  1992        PMID: 1396809     DOI: 10.1093/oxfordjournals.eurheartj.a060067

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  11 in total

1.  Validity of a modified shuttle test in adult cystic fibrosis.

Authors:  J Bradley; J Howard; E Wallace; S Elborn
Journal:  Thorax       Date:  1999-05       Impact factor: 9.139

2.  Comparison of shuttle walk with measured peak oxygen consumption in patients with operable lung cancer.

Authors:  T Win; A Jackson; A M Groves; L D Sharples; S C Charman; C M Laroche
Journal:  Thorax       Date:  2005-10-21       Impact factor: 9.139

3.  Collagen degrading activity associated with Mycobacterium species.

Authors:  F Massó; A Paéz; E Varela; L D de León; E Zenteno; L F Montaño
Journal:  Thorax       Date:  1999-05       Impact factor: 9.139

4.  Prognostic significance of blood pressure response to exercise in patients with systolic heart failure.

Authors:  Manolis S Kallistratos; Leonidas E Poulimenos; Antonios N Pavlidis; Athanasios Dritsas; Ioannis D Laoutaris; Athanasios J Manolis; Dennis V Cokkinos
Journal:  Heart Vessels       Date:  2011-01-26       Impact factor: 2.037

Review 5.  Exercise for patients with congestive heart failure.

Authors:  R J Shephard
Journal:  Sports Med       Date:  1997-02       Impact factor: 11.136

6.  The increased ventilatory response to exercise in chronic heart failure: relation to pulmonary pathology.

Authors:  A L Clark; M Volterrani; J W Swan; A J Coats
Journal:  Heart       Date:  1997-02       Impact factor: 5.994

7.  Heart Failure with Reduced Ejection Fraction and Prognostic Scales: The Impact of Exercise Modality in Cardiopulmonary Exercise Tests.

Authors:  Julia Herrero Huertas; Marta García Clemente; Beatriz Díaz Molina; José Luis Lambert Rodríguez; Marta Íscar Urrutia
Journal:  J Clin Med       Date:  2022-05-31       Impact factor: 4.964

8.  Exponential protocols for cardiopulmonary exercise testing on treadmill and cycle ergometer.

Authors:  J P Jamison; J Megarry; M Riley
Journal:  Eur J Appl Physiol       Date:  2009-09-22       Impact factor: 3.078

9.  Gas exchange responses to constant work rate exercise in chronic cardiac failure.

Authors:  M Riley; J Pórszász; C F Stanford; D P Nicholls
Journal:  Br Heart J       Date:  1994-08

10.  Effect of iron overload on exercise capacity in thalassemic patients with heart failure.

Authors:  Sophie Mavrogeni; Efstathios Gotsis; Dimitrios Verganelakis; Eleni Berdousis; Athanasios Dritsas; Genovefa Kolovou; Panagiotis Toulas; Vassilios Ladis
Journal:  Int J Cardiovasc Imaging       Date:  2009-08-13       Impact factor: 2.357

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.